Treatment of Actinic Cheilitis with Ingenol Mebutate Gel: Experience in Four Patients

The document reports on a study that evaluated the risk of sexual dysfunction in young men prescribed finasteride for androgenic alopecia (AA). The study analyzed data from an electronic medical record database of 157,998 healthy men under 42 years old with no prior sexual dysfunction, who were either exposed to finasteride at a daily oral dose ≤1.25 mg or not exposed to finasteride or any other 5-alpha reductase inhibitors. The results showed that men exposed to finasteride had a significantly increased risk of impotence (hazard ratio [HR] = 3.06, number needed to harm [NNH] = 129, P<.00017), increased use of phosphodiesterase-5 inhibitors (HR= 4.8, NNH = 70.2, P<.000001), and increased risk of diminished libido (HR= 4.9, NNH = 201, P <.0001) compared to men not exposed to the drug. The study concluded that there is a highly statistically significant risk of impotence, increased PDE5I use, and diminished libido in healthy men under 42 who were prescribed finasteride for AA, suggesting a need for increased awareness in the dermatology community regarding these risks. No commercial support was identified for the study.